| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Dale Okuno last filed a Form 4 in May 2020, as Director at PURE. Dale Okuno's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 5,520,540 shares of PURE. Net of sales, the PURE filings show accumulation of 787,473 shares.
Dale Okuno has 7 Form 4 filings on record from February 2019 to May 2020, all as Director at Pure Bioscience (PURE), 2019–2020.
The 11 reported transactions were 4 option or other derivative awards, 2 open-market sales, 2 open-market purchases and 1 stock award, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 2 purchases worth about $500K and 1 sale worth about $228K.
The largest open-market purchase was 714,285 shares of PURE at an average $0.35 on May 9, 2019, about $250K.
The only open-market sale was 788,880 shares of PURE at an average $0.29 on December 19, 2020, about $228K.
Shares as reported in the last Form 4 for each company; the most recent is from May 2020. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.